Crinetics Pharmaceuticals Inc (CRNX) Reports Increased R&D Investment Amidst Net Loss ... [Yahoo! Finance]
Crinetics Pharmaceuticals, Inc. (CRNX)
Last crinetics pharmaceuticals, inc. earnings: 3/9 04:10 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
General and Administrative Expenses : Rose to $58.1 million in 2023 from $42.4 million in 2022. Net Loss : Widened to $214.5 million in 2023 from $163.9 million in 2022. Revenue : Decreased slightly to $4.0 million in 2023 from $4.7 million in 2022. Cash Position : Strengthened with $558.6 million in cash, cash equivalents, and investments as of December 31, 2023. Upcoming Milestones : Topline results from Phase 3 PATHFNDR-2 study and Phase 2 carcinoid syndrome study expected in 2024. Private Placement : Announced a $350 million private placement equity financing to extend cash runway into 2028. Warning! GuruFocus has detected 7 Warning Signs with CRNX. On February 28, 2024, Crinetics Pharmaceuticals Inc ( NASDAQ:CRNX ) released its 8-K filing , detailing the financial results for the fourth quarter and full year ended December 31, 2023. The clinical-stage pharmaceutical company, which specializes in novel therapeutics for rare endocrine diseases and endocrine-related t
Show less
Read more
Impact Snapshot
Event Time:
CRNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRNX alerts
High impacting Crinetics Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CRNX
News
- Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More [Yahoo! Finance]Yahoo! Finance
- Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals [Yahoo! Finance]Yahoo! Finance
- Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its price target raised by analysts at Oppenheimer Holdings Inc. from $54.00 to $55.00. They now have an "outperform" rating on the stock.MarketBeat
- Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its price target raised by analysts at JMP Securities from $60.00 to $80.00. They now have a "market outperform" rating on the stock.MarketBeat
CRNX
Earnings
- 2/28/24 - Miss
CRNX
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form DEF
- CRNX's page on the SEC website